Cryopreservation impairs 3-D migration and cytotoxicity of natural killer cells.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
16 10 2020
16 10 2020
Historique:
received:
18
12
2019
accepted:
24
09
2020
entrez:
17
10
2020
pubmed:
18
10
2020
medline:
18
11
2020
Statut:
epublish
Résumé
Natural killer (NK) cells are important effector cells in the immune response to cancer. Clinical trials on adoptively transferred NK cells in patients with solid tumors, however, have thus far been unsuccessful. As NK cells need to pass stringent safety evaluation tests before clinical use, the cells are cryopreserved to bridge the necessary evaluation time. Standard degranulation and chromium release cytotoxicity assays confirm the ability of cryopreserved NK cells to kill target cells. Here, we report that tumor cells embedded in a 3-dimensional collagen gel, however, are killed by cryopreserved NK cells at a 5.6-fold lower rate compared to fresh NK cells. This difference is mainly caused by a 6-fold decrease in the fraction of motile NK cells after cryopreservation. These findings may explain the persistent failure of NK cell therapy in patients with solid tumors and highlight the crucial role of a 3-D environment for testing NK cell function.
Identifiants
pubmed: 33067467
doi: 10.1038/s41467-020-19094-0
pii: 10.1038/s41467-020-19094-0
pmc: PMC7568558
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5224Références
Leukemia. 2007 Feb;21(2):356-9; author reply 359
pubmed: 17251901
Blood. 2013 Feb 21;121(8):1326-34
pubmed: 23287857
Bone Marrow Transplant. 2003 Jul;32(2):177-86
pubmed: 12838283
N Engl J Med. 1985 Jun 6;312(23):1512-4
pubmed: 3990752
Methods Mol Biol. 2018;1803:231-241
pubmed: 29882143
Clin Cancer Res. 2011 Oct 1;17(19):6287-97
pubmed: 21844012
Blood. 2008 Aug 1;112(3):699-707
pubmed: 18519814
J Exp Clin Cancer Res. 2010 Oct 11;29:134
pubmed: 20937115
J Immunol Methods. 2014 Apr;406:1-9
pubmed: 24561308
Adv Sci (Weinh). 2019 Jan 27;6(6):1802045
pubmed: 30937270
Biochem Soc Trans. 1997 May;25(2):175S
pubmed: 9191219
Immunol Lett. 2017 Dec;192:35-41
pubmed: 28966059
Cancers (Basel). 2019 Aug 16;11(8):
pubmed: 31426437
J Immunol Methods. 1993 Sep 27;165(1):21-30
pubmed: 8409465
Front Immunol. 2014 Mar 07;5:80
pubmed: 24639676
Biol Blood Marrow Transplant. 2014 Aug;20(8):1252-7
pubmed: 24816582
J Transl Med. 2015 Aug 25;13:277
pubmed: 26303618
Int J Cancer. 2000 Dec 1;88(5):791-7
pubmed: 11072250
Inflamm Bowel Dis. 2017 Aug;23(8):1348-1359
pubmed: 28708802
Oncoimmunology. 2017 Mar 16;6(4):e1303586
pubmed: 28507811
Br J Haematol. 2018 Feb;180(4):534-544
pubmed: 29265182
Nat Med. 2003 Nov;9(11):1377-82
pubmed: 14528297
Front Immunol. 2017 May 31;8:631
pubmed: 28620386
Cytotherapy. 2016 Jun;18(6):754-9
pubmed: 27090754
Blood. 2015 Mar 12;125(11):1842-3
pubmed: 25766566
J Natl Cancer Inst. 1993 Apr 21;85(8):622-32
pubmed: 8468720
Front Immunol. 2017 Oct 26;8:1371
pubmed: 29123521
Oncoimmunology. 2016 Nov 22;5(12):e1250051
pubmed: 28123890
Front Immunol. 2012 Nov 29;3:347
pubmed: 23230434